EcoDrugPlus

Angiotensin Ii Receptor, Type 2

Ensembl ID : ENSSTUG00000023443
Gene Symbol: AGTR2
1 Cross references
179 Possible Orthologues:

Anti-Apoptotic Protein Nr13-Like

Ensembl ID : ENSSTUG00000011687
Gene Symbol: LOC115203341
3 Cross references
127 Possible Orthologues:

Anti-Apoptotic Protein Nr13-Like

Ensembl ID : ENSSTUG00000034876
Gene Symbol: LOC115166977
3 Cross references
127 Possible Orthologues:

Antithrombin-Iii-Like

Ensembl ID : ENSSTUG00000017485
Gene Symbol: LOC115158059
3 Cross references
195 Possible Orthologues:

Antithrombin-Iii-Like

Ensembl ID : ENSSTUG00000044974
Gene Symbol: LOC115151620
3 Cross references
195 Possible Orthologues:

Apelin Receptor B-Like

Ensembl ID : ENSSTUG00000008041
Gene Symbol: LOC115167714
3 Cross references
171 Possible Orthologues:

Apoptosis Regulator Bcl-2-Like

Ensembl ID : ENSSTUG00000017221
Gene Symbol: LOC115195542
3 Cross references
161 Possible Orthologues:

Apoptosis Regulator Bcl-2-Like

Ensembl ID : ENSSTUG00000029439
Gene Symbol: LOC115150453
3 Cross references
161 Possible Orthologues:

Arachidonate 12-Lipoxygenase, 12s-Type-Like

Ensembl ID : ENSSTUG00000013224
Gene Symbol: LOC115194626
3 Cross references
191 Possible Orthologues:

Arachidonate 12-Lipoxygenase, 12s-Type-Like

Ensembl ID : ENSSTUG00000015927
Gene Symbol: LOC115198574
3 Cross references
191 Possible Orthologues:

Arachidonate 5-Lipoxygenase-Activating Protein-Like

Ensembl ID : ENSSTUG00000035779
Gene Symbol: LOC115204605
3 Cross references
194 Possible Orthologues:

Arachidonate 5-Lipoxygenase-Activating Protein-Like

Ensembl ID : ENSSTUG00000012256
Gene Symbol: LOC115153845
3 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).